Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)

Trial Profile

Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2016

At a glance

  • Drugs Rucaparib (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms RIO
  • Most Recent Events

    • 19 Dec 2016 Status changed to active, no longer recruiting.
    • 11 Oct 2016 Recruitment is expected to complete early 2017, as per the trial design presented at 41st European Society for Medical Oncology Congress.
    • 11 Oct 2016 Trial design presented at 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top